Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Allergy Clin Immunol. 1993 Jul;92(1 Pt 2):200-2.

General pharmacology, pharmacokinetics, and toxicology of nedocromil sodium.

Author information

  • 1Eisons plc, Pharmaceutical Division, Loughborough, Leicestershire, United Kingdom.

Abstract

The pharmacokinetic properties of nedocromil sodium give this agent a high safety margin in the treatment of asthma. Only 5% to 10% of an inhaled dose is absorbed, primarily from the respiratory tract, but also from the secondary oral route. Nedocromil sodium has very rapid plasma clearance and is confined to the extravascular space. The drug is not metabolized in either humans or animals, which renders animal testing relevant to the safety of this compound in humans. Tests conducted in several models did not uncover any adverse effects, even at high infused or inhaled doses. Also, nedocromil did not appear to interact with a variety of other drugs that are likely to be used concomitantly. These data support the long-term use of nedocromil sodium at doses required for therapeutic efficacy.

PMID:
8393030
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk